Integra Lifesciences Holdings Corp (IART) Expected to Post Earnings of $0.61 Per Share

Share on StockTwits

Brokerages predict that Integra Lifesciences Holdings Corp (NASDAQ:IART) will announce earnings per share (EPS) of $0.61 for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Integra Lifesciences’ earnings. The lowest EPS estimate is $0.59 and the highest is $0.63. Integra Lifesciences posted earnings of $0.58 per share in the same quarter last year, which would indicate a positive year over year growth rate of 5.2%. The business is scheduled to report its next earnings report on Wednesday, April 24th.

On average, analysts expect that Integra Lifesciences will report full-year earnings of $2.68 per share for the current financial year, with EPS estimates ranging from $2.63 to $2.70. For the next year, analysts expect that the firm will report earnings of $2.99 per share, with EPS estimates ranging from $2.96 to $3.02. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Integra Lifesciences.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Thursday, February 21st. The life sciences company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.03. Integra Lifesciences had a return on equity of 16.02% and a net margin of 4.13%. The business had revenue of $383.30 million during the quarter, compared to analysts’ expectations of $382.33 million. During the same quarter last year, the business posted $0.64 EPS. The business’s revenue was up 4.0% on a year-over-year basis.

IART has been the subject of several research analyst reports. Zacks Investment Research upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Monday, February 4th. BidaskClub upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. Credit Suisse Group initiated coverage on Integra Lifesciences in a report on Monday, December 17th. They issued an “outperform” rating and a $57.00 price objective for the company. Finally, SunTrust Banks initiated coverage on Integra Lifesciences in a report on Thursday, January 3rd. They issued a “buy” rating and a $56.00 price objective for the company. One analyst has rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $60.67.

Large investors have recently made changes to their positions in the company. Oregon Public Employees Retirement Fund increased its position in Integra Lifesciences by 4,410.0% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,254,051 shares of the life sciences company’s stock valued at $28,000 after buying an additional 1,226,245 shares in the last quarter. Enlightenment Research LLC bought a new position in Integra Lifesciences during the 4th quarter valued at approximately $32,000. Legacy Financial Advisors Inc. bought a new position in Integra Lifesciences during the 4th quarter valued at approximately $33,000. Fort L.P. bought a new position in Integra Lifesciences during the 4th quarter valued at approximately $34,000. Finally, Executive Wealth Management LLC bought a new position in Integra Lifesciences during the 4th quarter valued at approximately $38,000. 83.11% of the stock is owned by hedge funds and other institutional investors.

NASDAQ IART opened at $56.14 on Friday. Integra Lifesciences has a fifty-two week low of $42.14 and a fifty-two week high of $67.50. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.95 and a quick ratio of 1.88. The company has a market capitalization of $4.72 billion, a price-to-earnings ratio of 23.20, a price-to-earnings-growth ratio of 1.63 and a beta of 0.96.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Recommended Story: Derivative

Get a free copy of the Zacks research report on Integra Lifesciences (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Edap Tms  Given a $7.00 Price Target at HC Wainwright
Edap Tms Given a $7.00 Price Target at HC Wainwright
Dynex Capital  Upgraded by Zacks Investment Research to “Hold”
Dynex Capital Upgraded by Zacks Investment Research to “Hold”
Carter’s, Inc.  Shares Sold by American International Group Inc.
Carter’s, Inc. Shares Sold by American International Group Inc.
American Money Management LLC Has $3.98 Million Stake in Paychex, Inc.
American Money Management LLC Has $3.98 Million Stake in Paychex, Inc.
Marathon Petroleum Corp  Shares Sold by American Financial Network Advisory Services LLC
Marathon Petroleum Corp Shares Sold by American Financial Network Advisory Services LLC
Alpha Quant Advisors LLC Purchases New Holdings in Quest Diagnostics Inc
Alpha Quant Advisors LLC Purchases New Holdings in Quest Diagnostics Inc


© 2006-2019 Ticker Report